Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Hepatitis A vaccine (inactivated, adsorbed) inj 1ml pfs
140400030AAACAC
|
Hepatitis A | Hepatitis A | Immunological Products and Vaccines | 270 |
|
Menitorix vacc inj 0.5ml vials
1404000AFBBAAAA
|
Menitorix | Haemophilus influenzae B/meningococcal C | Immunological Products and Vaccines | 149 |
|
HBVAXPRO 5micrograms/0.5ml vacc inj pre-filled syringes
1404000G0BEADAF
|
HBVAXPRO | Hepatitis B | Immunological Products and Vaccines | 146 |
|
Hepatitis B (rDNA) 20micrograms/1ml vacc inj pfs
1404000G0AAACAC
|
Hepatitis B | Hepatitis B | Immunological Products and Vaccines | 140 |
|
Varilrix vacc inj 0.5ml vials
140400050BBAAAB
|
Varilrix | Varicella vaccine live | Immunological Products and Vaccines | 137 |
|
Varivax vacc inj 0.5ml vials
140400050BCAAAC
|
Varivax | Varicella vaccine live | Immunological Products and Vaccines | 122 |
|
Varicella vacc (live) inj 0.5ml vials
140400050AAABAB
|
Varicella Vaccine | Varicella vaccine live | Immunological Products and Vaccines | 119 |
|
Hep A GBM strain (ads)/Typhoid polysacch vacc inj 1ml pfs
1404000ADAAABAB
|
Hepatitis A/typhoid | Hepatitis A/typhoid vaccine | Immunological Products and Vaccines | 116 |
|
Hep A (inact)/Hep B (rDNA) vacc (ads) inj 1ml pfs
140400070AAAAAA
|
Hepatitis A/B | Hepatitis A/hepatitis B | Immunological Products and Vaccines | 107 |
|
Cholera vacc (rcmb, live, oral) efferv pdr and pdr for susp
1404000E0AAAKAK
|
Cholera (Vaccine) | Cholera | Immunological Products and Vaccines | 104 |
|
MenQuadfi vaccine solution for injection 0.5ml vials
1404000X0BKAAAH
|
MenQuadfi | Meningococcal A + C + W135 + Y vaccine | Immunological Products and Vaccines | 90 |
|
Gardasil 9 vacc inj 0.5ml pre-filled syringes
1404000AMBBAAAA
|
Gardasil 9 | Humpapvirus(Type 6,11,16,18,31,33,45,52,58) | Immunological Products and Vaccines | 85 |
|
Adacel vacc inj 0.5ml pre-filled syringes
1404000F0BTAABD
|
Adacel | Diphtheria | Immunological Products and Vaccines | 83 |
|
Vivotif vaccine gastro-resistant capsules
1404000S0BDAAAC
|
Vivotif | Typhoid | Immunological Products and Vaccines | 76 |
|
Rabipur vacc inj 1ml pre-filled syringes
1404000N0BDABAF
|
Rabipur | Rabies | Immunological Products and Vaccines | 75 |
|
Infanrix-IPV + Hib vacc inj 0.5ml pre-filled syringes
1404000F0BNABBB
|
Infanrix-IPV | Diphtheria | Immunological Products and Vaccines | 71 |
|
Hepatitis A vaccine (inactivated, adsorbed) inj 0.5ml pfs
140400030AAADAD
|
Hepatitis A | Hepatitis A | Immunological Products and Vaccines | 69 |
|
Hepatitis B (rDNA) 10micrograms/0.5ml vacc inj pfs
1404000G0AAAIAI
|
Hepatitis B | Hepatitis B | Immunological Products and Vaccines | 66 |
|
Gardasil vacc inj 0.5ml pre-filled syringes
1404000AHBBAAAA
|
Gardasil | Human papillomavirus (Type 6,11,16,18) | Immunological Products and Vaccines | 65 |
|
Menveo vaccine inj 0.5ml vials
1404000X0BIAAAC
|
Menveo | Meningococcal A + C + W135 + Y vaccine | Immunological Products and Vaccines | 65 |
|
Shingles (Herpes Zoster) adjuvanted rcmb vacc inj 0.5ml
1404000ALAAACAC
|
Shingles (H/Z) | Shingles (H/Z) | Immunological Products and Vaccines | 61 |
|
Typhoid vacc (live, oral, strain ty21a) gast res caps
1404000S0AAACAC
|
Typhoid Vaccine | Typhoid | Immunological Products and Vaccines | 55 |
|
Hep A (inact)/Hep B (rDNA) vacc (ads) inj 0.5ml pfs
140400070AAABAB
|
Hepatitis A/B | Hepatitis A/hepatitis B | Immunological Products and Vaccines | 53 |
|
Influenza vaccine (split virion, inactivated) inj 0.5ml pfs
1404000H0AAAKAK
|
Influenza | Influenza | Immunological Products and Vaccines | 53 |
|
Varicella vacc live inj 0.5ml vials
140400050AAACAC
|
Varicella Vaccine | Varicella vaccine live | Immunological Products and Vaccines | 53 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.